# Spondyloarthritis Studies and Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the classification, diagnosis, and treatment of spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis. It covers the development of new classification criteria, assessment of disease activity, use of biologic therapies such as tumor necrosis factor inhibitors and interleukin-17 inhibitors, and the impact of genetic factors like HLA-B27. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11092 |
| Works | 449 |

## Topic papers all

Showing 15 of 449.

- [2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative](https://scholariq.org/papers/2010-rheumatoid-arthritis-classification-criteria-an-american-college-of-2/)
- [2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative](https://scholariq.org/papers/2010-rheumatoid-arthritis-classification-criteria-an-american-college-of/)
- [Classification criteria for psoriatic arthritis: Development of new criteria from a large international study](https://scholariq.org/papers/classification-criteria-for-psoriatic-arthritis-development-of-new-criteria-from/)
- [Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/infliximab-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis/)
- [2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid/)
- [Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-selected-musculoskeletal-disorders/)
- [Diagnosis and Management of Rheumatoid Arthritis](https://scholariq.org/papers/diagnosis-and-management-of-rheumatoid-arthritis/)
- [Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-other-rheumatic-conditions-in-the-2/)
- [Risk of Myocardial Infarction in Patients With Psoriasis](https://scholariq.org/papers/risk-of-myocardial-infarction-in-patients-with-psoriasis/)
- [The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment](https://scholariq.org/papers/the-premier-study-a-multicenter-randomized-double-blind-clinical-trial-of/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [Psoriatic arthritis: epidemiology, clinical features, course, and outcome](https://scholariq.org/papers/psoriatic-arthritis-epidemiology-clinical-features-course-and-outcome/)
- [Psoriatic Arthritis](https://scholariq.org/papers/psoriatic-arthritis/)
- [Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study](https://scholariq.org/papers/frequency-of-infection-in-patients-with-rheumatoid-arthritis-compared-with/)

## Topic primary papers

Showing 15 of 105.

- [Classification criteria for psoriatic arthritis: Development of new criteria from a large international study](https://scholariq.org/papers/classification-criteria-for-psoriatic-arthritis-development-of-new-criteria-from/)
- [Psoriatic arthritis: epidemiology, clinical features, course, and outcome](https://scholariq.org/papers/psoriatic-arthritis-epidemiology-clinical-features-course-and-outcome/)
- [Psoriatic Arthritis](https://scholariq.org/papers/psoriatic-arthritis/)
- [Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis](https://scholariq.org/papers/development-of-an-asas-endorsed-disease-activity-score-asdas-in-patients-with/)
- [2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis](https://scholariq.org/papers/2010-update-of-the-asas-eular-recommendations-for-the-management-of-ankylosing/)
- [The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal](https://scholariq.org/papers/the-development-of-assessment-of-spondyloarthritis-international-society/)
- [European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update](https://scholariq.org/papers/european-league-against-rheumatism-eular-recommendations-for-the-management-of/)
- [Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies](https://scholariq.org/papers/prevalence-of-psoriatic-arthritis-in-patients-with-psoriasis-a-systematic-review/)
- [Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)](https://scholariq.org/papers/sustained-benefits-of-infliximab-therapy-for-dermatologic-and-articular/)
- [ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis](https://scholariq.org/papers/asdas-a-highly-discriminatory-asas-endorsed-disease-activity-score-in-patients/)
- [Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based study](https://scholariq.org/papers/incidence-and-clinical-predictors-of-psoriatic-arthritis-in-patients-with/)
- [Epidemiology of psoriatic arthritis in the population of the United States](https://scholariq.org/papers/epidemiology-of-psoriatic-arthritis-in-the-population-of-the-united-states/)
- [Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1](https://scholariq.org/papers/genome-wide-association-analysis-identifies-new-susceptibility-loci-for-behcet-s/)
- [Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors](https://scholariq.org/papers/tofacitinib-for-psoriatic-arthritis-in-patients-with-an-inadequate-response-to/)
- [Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial](https://scholariq.org/papers/ixekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis-and-an/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.